Galderma has received its first three Pliaglis marketing licenses from E.U. countries, triggering a $6 million milestone payment to partner Nuvo Research. The milestone payments are due on the launch of Pliaglis in the approved countries or six months from the date of marketing approval. The payments are expected in December 2012 ($5.0 million) and January 2013 ($1.0 million). Galderma plans to launch Pliaglis in the E.U. and other territories in 1H13.   “We are extremely pleased that Plia...